Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-κB inhibitor, through downregulation of NFATc1

Journal of Bone and Mineral Research

Volumn 20, Issue 4, 2005, Pages 653-662

  Takatsuna, Hiroshi ^a   Asagiri, Masataka ^b   Kubota, Takeshi ^a   Oka, Kotaro ^a   Osada, Toshihiro ^a   Sugiyama, Chie ^a   Saito, Hiroaki ^b   Aoki, Kazuhiro ^b   Ohya, Keiichi ^b   Takayanagi, Hiroshi ^b,c   Umezawa, Kazuo ^a  

^a KEIO UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Bone resorption; NF B; NFATc1; Osteoclastogenesis; RANKL

Indexed keywords

COLONY STIMULATING FACTOR 1; DEHYDROXYMETHYLEPOXYQUINOMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN; PROTEIN INHIBITOR; RETROVIRUS VECTOR; TRACP PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ARTICLE; BIOASSAY; BONE DESTRUCTION; BONE EROSION; BONE MARROW CELL; BONE MARROW DERIVED MONOCYTE MACROPHAGE PRECURSOR CELL; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; MULTINUCLEAR CELL; NONHUMAN; ONCOGENE C FOS; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PIT FORMATION ASSAY; STEM CELL;

ANIMALS; BENZAMIDES; BONE MARROW CELLS; BONE RESORPTION; CARRIER PROTEINS; CELL DIFFERENTIATION; CYCLOHEXANONES; DOWN-REGULATION; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR STRUCTURE; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PHOSPHORYLATION; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 20144373896     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.041213     Document Type: Article

References (44)

1. Goldring SR, Gravallese EM 2002 Pathogenesis of bone lesions in rheumatoid arthritis. Curr Rheumatol Rep 4:226-231.
2. Feldmann M, Brennan FM, Maini RN 1996 Rheumatoid arthritis (review). Cell 85:307-310.
3. Romas E, Bakharevski O, Hards DK, Kartsogiannis V, Quinn JM, Ryan PF, Martin TJ, Gillespie MT 2000 Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 43:821-826.
4. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S 2000 Involvement of RANKL/ODF in osteoclastogenesis from synoviocyte in RA. Arthritis Rheum 43:259-269.
5. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, Benoist C, Gravallese EM 2001 TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159:1689-1699.
6. Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, Athanasou NA 1996 The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 137:4058-4060.
7. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacy DL, Boyle WJ 2000 RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97:1566-1571.
8. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Setialdi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
9. Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y 1998 The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor. J Biol Chem 273:28355-28359.
10. Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB 1998 Characterization of the intercellular domain of receptor activator of NF-κB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-κB and c-Jun N-terminal kinase. J Biol Chem 273:20551-20555.
11. Darnay BG, Ni J, Moore PA, Aggarwal BB 1999 Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-κB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem 274:7724-7731.
12. Darnay BG, Aggarwal BB 1999 Signal transduction by tumor necrosis factor and tumor necrosis factor related ligands and their receptors. Ann Rheum Dis 58(Suppl 1):I2-I13.
13. Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, Nakao K, Nakamura K, Katsuki M, Yamamoto T, Inoue J-I 1999 Severe osteopetrosis, defective interleuikin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4:353-362.
14. Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S, Inoue J-I 2001 Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J 20:1271-1280.
15. Wang ZQ, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF 1992 Bone and hematopoietic defects in mice lacking c-fos. Nature 360:741-745.
16. Johnson RS, Spiegelman BM, Papaioannou V 1992 Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71:577-586.
17. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF 1994 c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266:443-448.
18. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wagner EF, Taniguchi T 2002 RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature 416:744-749.
19. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J-I, Wagner EF, Mak TW, Kodama T, Taniguchi T 2002 Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889-901.
20. Galibert L, Tometsko ME, Anderson DM, Cosman D, Dougall WC 1998 The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-κB, a member of the TNFR superfamily. J Biol Chem 273:34120-34127.
21. Kim HH, Lee DE, Shin JN, Lee YS, Jeon YM, Chung CH, Ni J, Kwon BS, Lee ZH 1999 Receptor activator of NF-κB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. FEBS Lett 443:297-302.
22. Ye H, Arron JR, Lamothe B, Cirilli M, Kobayashi T, Shevde NK, Segal D, Dzivenu OK, Vologodskaia M, Yim M, Du K, Singh S, Pike JW, Darnay BG, Choi Y, Wu H 2002 Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418:443-147.
23. Mizukami J, Takaesu G, Akatsuka H, Sakurai H, Ninomiya-Tsuji J, Matsumoto K, Sakurai N 2002 Receptor activator of NF-κB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, TRAF6. Mol Cell Biol 22:992-1000.
24. Beg AA, Ruben SM, Scheinman RI, Haskill S, Rosen CA, Baldwin AS Jr 1992 IκB interacts with the nuclear localization sequences of the subunits of NF-κB: A mechanism for cytoplasmic retention. Genes Dev 6:1899-1913.
25. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U 1997 Requirement for NF-κB in osteoclast and B-cell development. Genes Dev 11:3482-3496.
26. Matsumoto N, Ariga A, To-e S, Nakamura H, Agata N, Hirano S, Inoue J-I, Umezawa K 2000 Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett 10:865-869.
27. Umezawa K, Ariga A, Matsumoto N 2000 Naturally occurring and synthetic inhibitors of NF-κB functions. Anticancer Drug Des 15:239-244.
28. Kikuchi E, Horiguchi Y, Nakashima J, Kuroda K, Oya M, Ohigashi T, Takahashi N, Shima Y, Umezawa K, Murai M 2003 Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. Cancer Res 63:107-110.
29. Miyajima A, Kosaka T, Seta K, Asano T, Umezawa K, Hayakawa M 2003 Novel nuclear factor kappa B activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction. J Urol 169:1559-1563.
30. Ariga A, Namekawa J-I, Matsumoto N, Inoue J-I, Umezawa K 2002 Inhibition of tumor necrosis factor-α-induced nuclear translocation and activation of NF-κB by dehydroxymethylepoxyquinomicine. J Biol Chem 277:24625-24630.
31. Suzuki Y, Sugiyama C, Ohno O, Umeazwa K 2004 Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF-κB inhibitor. Tetrahedron 60:7061-7066.
32. Andrews NC, Faller DV 1991 A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19:2449-2455.
33. Abu-Amer Y, Dowdy SF, Ross FP, Clohisy JC, Teitelbaum SL 2001 TAT fusion proteins containing tyrosine 42-deleted IκBα arrest osteoclastogenesis. J Biol Chem 276:30499-30503.
34. Clohisy JC, Roy BC, Biondo C, Frazier E, Willis D, Teitelbaum SL, Abu-Amer Y 2003 Direct inhibition of NF-κB blocks bone erosion associated with inflammatory arthritis. J Immunol 171:5547-5553.
35. Hirotani H, Tuohy NA, Woo JH, Stern PH, Clipstone NA 2004 The calcineurin/NFAT signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J Biol Chem 279:13984-13992.
36. Urushibara M, Takayanagi H, Koga T, Kim S, Isobe M, Morishita Y, Nakagawa T, Loeffler M, Kodama T, Kurosawa H, Taniguchi T 2004 The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-κB ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum 50:794-804.
37. Yamamoto Y, Gaynor RB 2001 Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 107:135-142.
38. Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, Xu J 2003 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-κB activation. J Bone Miner Res 18:2159-2168.
39. Lee SE, Woo KM, Kim SY, Kim H-M, Kwack K, Lee ZH, Kim H-H 2002 The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 30:71-77.
40. Wei S, Wang MW, Teitelbaum SL, Ross FP 2002 Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-κB and mitogen-activated protein kinase signaling. J Biol Chem 277:6622-6630.
41. Kawaida R, Ohtsuka T, Okutsu J, Takahashi T, Kadono Y, Oda H, Hikita A, Nakamura K, Tanaka S, Furukawa H 2003 Jun dimerization protein 2 (JDP2), a member of AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL. J Exp Med 197:1029-1035.
42. Hotokezaka H, Sakai E, Kanaoka K, Saito K, Matsuo K-I, Kitaura H, Yoshida N, Nakayama K 2002 U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 277:47366-47372.
43. Miyazaki T, Katagiri H, Kanegae Y, Takayanagi H, Sawada Y, Yamamoto A, Pando MP, Asano T, Verma IM, Oda H, Nakamura K, Tanaka S 2000 Reciprocal role of ERK and NF-κB pathways in survival and activation of osteoclasts. J Cell Biol 148:333-342.
44. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, Sudo T, Kojima T, Okamoto F, Fukushima H, Okabe K, Ohya K, Ghosh S 2004 Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 10:617-624.